Thursday, Cynosure, Inc. (CYNO) announced statically significant efficacy results from two post-marketing studies of Smartlipo MPX that demonstrated its skin-tightening and tissue-shrinking effects. The company would present the data American Society for Laser Medicine and Surgery Annual Conferenc.
The first post marketing study was a randomized, blinded one that compared the Smartlipo MPX workstation against liposuction for their ability to improve skin elasticity and tighten tissue. The study involved 10 women who received a single treatment with liposuction on one side of the abdomen and the dual-wavelength Smartlipo MPX on the other side.
Skin shrinkage was evaluated through photographic imaging and measurement of temporary ink markings, while skin tightening was evaluated with the use of an elasticity device. Measurements were taken at baseline and at one and three months post-treatment.
The company said the results of the study showed that at one and three months, skin treated with Smartlipo MPX had a statistically significant higher skin shrinkage ratio than skin treated with liposuction only. Cynosure said that of the nine patients who were fully evaluated, eight or 89%, had an average of 54% greater shrinkage at three months on the Smartlipo MPX side than the liposuction side. The study also showed a statistically significant difference in skin tightening, as at three months, the average improvement in skin tightening was 62% with Smartlipo MPX compared with a 5% improvement on the side treated with liposuction.
The other study involved a total of 20 subjects who had unwanted localized areas of fat and skin laxity. In a subset of five patients, skin tightening through surface area reduction was measured with the use of temporary tattoo markings.
The company said that in addition to a reduction in localized fat deposits, the study demonstrated new collagen formation and an 18% decrease in skin surface area.
Commenting on the positive results from the two studies, Cynosure President and CEO Michael Davin said, "These studies provide powerful scientific evidence that affirms the dramatic results already being observed by physicians and patients. We believe this research, and subsequent studies, will drive further adoption of Smartlipo MPX and amplify the benefits of our laser lipolysis technology as a complete solution for fat removal with the potential added advantage of skin tightening and body sculpting."
CYNO is currently trading at $6.70, up 8.59% or $0.53, on a volume of 81,269 shares on the Nasdaq Exchange.
For comments and feedback: editorial@rttnews.com